Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D81WHA
|
|||
| Drug Name |
AZD8233
|
|||
| Synonyms |
ION449
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z] | Phase 2 | [1] | |
| Hypercholesterolaemia [ICD-11: 5C80.0; ICD-9: 272] | Phase 2 | [1] | ||
| Company |
AstraZeneca; Ionis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | PCSK9 messenger RNA (PCSK9 mRNA) | Target Info | Inhibitor | [2] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04964557) A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia. U.S.National Institutes of Health. | |||
| REF 2 | AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. Br J Clin Pharmacol. 2022 Nov;88(11):4839-4844. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.